The late phase of preconditioning and its natural clinical application - Gene therapy

Roberto Bolli, Qian Hong Li, Xian Liang Tang, Yiru Guo, Yu Ting Xuan, Gregg Rokosh, Buddhadeb Dawn

Research output: Contribution to journalReview articlepeer-review

59 Scopus citations

Abstract

There is little doubt that the discovery of ischemic preconditioning (PC) has been one of the fundamental milestones in the field of ischemic biology in the past 20 years. The purpose of this article is to review the pathophysiology and molecular basis of the late phase of myocardial PC. The exploitation of late PC for the development of novel gene therapy strategies aimed at inducing a permanently preconditioned cardiac phenotype (prophylactic cardioprotection) will also be discussed. Deciphering the mechanism of late PC has not only conceptual interest but also a considerable therapeutic implications, since transfer of the genes that underlie late PC would be expected to replicate the salubrious effects of this response of the heart to stress.

Original languageEnglish
Pages (from-to)189-199
Number of pages11
JournalHeart Failure Reviews
Volume12
Issue number3-4
DOIs
StatePublished - Dec 2007

Keywords

  • Cyclooxygenase-2
  • Late preconditioning
  • Nitric oxide synthase
  • Protection

Fingerprint

Dive into the research topics of 'The late phase of preconditioning and its natural clinical application - Gene therapy'. Together they form a unique fingerprint.

Cite this